Antidepressant activity of anti-cytokine treatment: A systematic review and meta- analysis of clinical trials of chronic inflammatory conditions

Kappelmann, Nils; Lewis, Glyn; Dantzer, Robert; Jones, Peter; Khandaker, Golam M.

doi:10.1016/j.bbi.2017.07.023

Cited by 17 publications

(14 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, the question of addressing the inflammatory component associated with this type of depression is compelling. 43 Successful identification of preferential response to treatment would escalate the selection of antidepressant pharmacotherapy from a trial-and-error endeavor to a practice that uses a predictive biomarker in its treatment of depression. Enhanced depression treatment would be especially helpful in the lung cancer setting, where the prevalence of depression is the highest of all cancer subtypes, and its treatment could fulfill this unmet need.…”

Section: Discussionmentioning

confidence: 99%

C‐reactive protein and its association with depression in patients receiving treatment for metastatic lung cancer

McFarland

Shaffer

Breitbart

et al. 2018

Cancer

View full text Add to dashboard Cite

BACKGROUND: Depression is highly prevalent in lung cancer. Although there is a known association between inflammation and depression, this relationship has not been examined in patients with lung cancer who undergo treatment with immune and other targeted drug therapies. Peripheral blood C-reactive protein (CRP), a marker of systemic inflammation, may help identify metastatic lung cancer patients with inflammation-associated depression. METHOD: Patients with metastatic lung cancer undergoing treatment were evaluated for depression using the Hospital Anxiety and Depression Scale (HADS). Inflammation (CRP and CRP cutoffs ≥1 and ≥3 mg/mL) and demographic and treatment variables were analyzed for association with depression. RESULTS: One hundred nine consecutive participants exhibited an average plasma CRP concentration of 1.79 mg/mL (median, 0.75 mg/mL [standard deviation, 2.5 mg/mL), and 20.7% had a CRP concentration of ≥3.0 mg/mL; 23.9% met depression screening criteria (HADS ≥8). A log transformation of CRP was significantly correlated with depression severity (r = 0.47, P < .001). CRP was the only covariate to predict depression severity (P = .008) in a multivariate model including lung cancer disease subtype and type of systemic treatment. Receiver operating characteristic analysis indicated that CRP had moderate predictive accuracy in identifying elevated depression (area under the curve = 0.74). A cutoff of CRP ≥3.0 generated high specificity (88%) but identified only 50% of those with elevated depression. CONCLUSION: Elevated CRP is associated with depression in patients with metastatic lung cancer. Thus, CRP may identify a subset of lung cancer patients with inflammation-induced depression and may be useful in predicting response to treatments that target inflammation or its downstream mediators on the brain.

show abstract

Section: Discussionmentioning

confidence: 99%

C‐reactive protein and its association with depression in patients receiving treatment for metastatic lung cancer

McFarland

Shaffer

Breitbart

et al. 2018

Cancer

View full text Add to dashboard Cite

show abstract

“…It is possible that there may be "subtypes" of CRF driven by different processes, similar to the idea of an inflammatory subtype of depression, that could be used to direct interventions. 122 For example, anti-cytokine therapies may be beneficial for patients with elevated inflammation, 28,123 although concerns about adverse effects limit the use of these agents in patients with cancer. Pharmacologic agents also could be used to target neurotransmitter, neuro-immune, and other systems related to fatigue (eg, buproprion, minocycline), whereas bright-light therapy could target circadian rhythm disturbance.…”

Section: Summary and Implications For Interventionmentioning

confidence: 99%

The role of neuro‐immune interactions in cancer‐related fatigue: Biobehavioral risk factors and mechanisms

Bower

2019

Cancer

133

120

View full text Add to dashboard Cite

Fatigue is a common and distressing symptom in both patients with cancer and cancer survivors. There is substantial variation in the severity and persistence of cancer‐related fatigue that may be driven by individual differences in host factors, including characteristics that predate the cancer experience as well as responses to cancer and its treatment. This review examines biobehavioral risk factors linked to fatigue and the mechanisms through which they influence fatigue across the cancer continuum, with a focus on neuro‐immune processes. Among psychosocial risk factors, childhood adversity is a strong and consistent predictor of cancer‐related fatigue; other risk factors include history of depression, catastrophizing, lack of physical activity, and sleep disturbance, with compelling preliminary evidence for loneliness and trait anxiety. Among biologic systems, initial work suggests that alterations in immune, neuroendocrine, and neural processes are associated with fatigue. The identification of key risk factors and underlying mechanisms is critical for the development and deployment of targeted interventions to reduce the burden of fatigue in the growing population of cancer survivors. Given the multidimensional nature of fatigue, interventions that influence multiple systems may be most effective.

show abstract

“…84,[86][87][88] Additionally, various anti-cytokine therapies have been reported to improve depression symptoms in individuals with inflammatory conditions. 89 Inflammatory marker levels are increased in the central nervous system (CNS) of individuals with depression and SIB (Table 3). [90][91][92][93][94][95][96][97][98] Toll-like receptor 3 and TLR4 protein and mRNA levels were observed to be elevated in the brains of individuals who had completed suicide, regardless of the presence of depression, compared with non-suicide control individuals.…”

Section: Mental Health and Sib Measures In Dermatology Clinical Studiesmentioning

confidence: 99%

Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression

Koo

Marangell

Nakamura

et al. 2017

Acad Dermatol Venereol

167

152

View full text Add to dashboard Cite

Psoriasis can be a socially isolating disease due to debilitating physical symptoms and the stigma patients feel because of the appearance of their skin. Mental health comorbidities such as anxiety, depression and suicidal ideation and behaviour (SIB) are prevalent in patients with psoriasis. Patients with mild psoriasis can experience psychiatric comorbidities; however, disorders such as depression and SIB are more common in patients with severe psoriasis or psoriatic arthritis. Psychiatric disorders can both result from and contribute to progression of psoriasis, suggesting that psoriasis and psychiatric conditions, such as depression, may have overlapping biological mechanisms. Proinflammatory cytokines such as interleukin (IL)-1 and IL-6 are elevated in both psoriasis and depression, indicating that the inflammatory process may be involved in the progression of both diseases. Elevated cytokine levels in the central nervous system cause physiologic and biochemical changes that may contribute to the development of depression. In this review of the literature, we discuss the evidence that supports the association of psoriasis with mental health disorders and the tools used to detect the presence of these comorbidities. Additionally, we review the most prominent hypotheses on the mechanisms by which the inflammatory response and elevated cytokines can cause depression. These results highlight the role that systemic inflammation plays in the various mental health comorbidities associated with psoriasis, including depression and SIB.

show abstract

Antidepressant activity of anti-cytokine treatment: A systematic review and meta- analysis of clinical trials of chronic inflammatory conditions

Cited by 17 publications

References 56 publications

C‐reactive protein and its association with depression in patients receiving treatment for metastatic lung cancer

C‐reactive protein and its association with depression in patients receiving treatment for metastatic lung cancer

The role of neuro‐immune interactions in cancer‐related fatigue: Biobehavioral risk factors and mechanisms

Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression

Contact Info

Product

Resources

About